Literature DB >> 23398500

Myasthenia gravis--treatment of acute severe exacerbations in the intensive care unit results in a favourable long-term prognosis.

J Spillane1, N P Hirsch, D M Kullmann, C Taylor, R S Howard.   

Abstract

BACKGROUND AND
PURPOSE: Acute severe exacerbations of myasthenia gravis (MG) are common in both early and late onset MG. We wished to examine the current management in the intensive care unit (ICU) of severe exacerbations of MG and to study the long-term prognosis of MG following discharge from the ICU.
METHODS: We retrospectively reviewed the medical records of all patients admitted to a specialist neuro-ICU with acute exacerbations of MG over a 12-year period.
RESULTS: We identified 38 patients. Over 60% were over the age of 50 years, and MG was newly diagnosed in over 40%. Intubation was required in 63%, and over 90% of patients were treated with prednisolone and/or intravenous immunoglobulin. Four patients died in hospital. The remainder of patients were followed up for a mean of 4 years, and the majority were either asymptomatic or had mild symptoms of MG at clinical review.
CONCLUSIONS: Despite the significant morbidity and mortality associated with severe exacerbations of MG, specialized neurointensive care can result in a good long-term prognosis in both early- and late-onset MG.
© 2013 The Author(s) European Journal of Neurology © 2013 EFNS.

Entities:  

Keywords:  intensive care; myasthenia gravis; myasthenic crisis

Mesh:

Substances:

Year:  2013        PMID: 23398500     DOI: 10.1111/ene.12115

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  7 in total

1.  It's getting better all the time? Using secular trends to understand the impact of neurocritical care.

Authors:  J Claude Hemphill
Journal:  Intensive Care Med       Date:  2013-06-27       Impact factor: 17.440

2.  Myasthenia gravis treated in the neurology intensive care unit: a 14-year single-centre experience.

Authors:  Mirjana Zdraljevic; Stojan Peric; Marta Jeremic; Dragana Lavrnic; Ivana Basta; Ljiljana Hajdukovic; Dejana R Jovanovic; Ivana Berisavac
Journal:  Neurol Sci       Date:  2022-09-09       Impact factor: 3.830

3.  Sniffing out a hidden cause of breathlessness.

Authors:  Alexandra Marie Nanzer; John Janssen; Matthew Hind
Journal:  BMJ Case Rep       Date:  2014-06-27

4.  Comorbidities and Long-Term Outcomes in a Cohort with Myasthenic Crisis: Experiences from a Tertiary Care Center.

Authors:  Ajith Sivadasan; Mathew Alexander; Sanjith Aaron; Vivek Mathew; Shalini Nair; Karthik Muthusamy; A T Prabhakar; Rohit N Benjamin; Atif Shaikh; Gideon Rynjah
Journal:  Ann Indian Acad Neurol       Date:  2019-10-25       Impact factor: 1.383

5.  Seronegative myasthenic crisis: a multicenter analysis.

Authors:  Philipp Mergenthaler; Henning R Stetefeld; Christian Dohmen; Siegfried Kohler; Silvia Schönenberger; Julian Bösel; Stefan T Gerner; Hagen B Huttner; Hauke Schneider; Heinz Reichmann; Hannah Fuhrer; Benjamin Berger; Jan Zinke; Anke Alberty; Ingo Kleiter; Christiane Schneider-Gold; Christian Roth; Juliane Dunkel; Andreas Steinbrecher; Andrea Thieme; De-Hyung Lee; Ralf A Linker; Klemens Angstwurm; Andreas Meisel; Bernhard Neumann
Journal:  J Neurol       Date:  2022-04-07       Impact factor: 4.849

6.  Utilization of Decision Tree Algorithms for Supporting the Prediction of Intensive Care Unit Admission of Myasthenia Gravis: A Machine Learning-Based Approach.

Authors:  Che-Cheng Chang; Jiann-Horng Yeh; Hou-Chang Chiu; Yen-Ming Chen; Mao-Jhen Jhou; Tzu-Chi Liu; Chi-Jie Lu
Journal:  J Pers Med       Date:  2022-01-02

7.  MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation.

Authors:  Nicole König; Henning R Stetefeld; Christian Dohmen; Philipp Mergenthaler; Siegfried Kohler; Silvia Schönenberger; Julian Bösel; De-Hyung Lee; Stefan T Gerner; Hagen B Huttner; Hauke Schneider; Heinz Reichmann; Hannah Fuhrer; Benjamin Berger; Jan Zinke; Anke Alberty; Ingo Kleiter; Christiane Schneider-Gold; Christian Roth; Juliane Dunkel; Andreas Steinbrecher; Andrea Thieme; Felix Schlachetzki; Ralf A Linker; Klemens Angstwurm; Andreas Meisel; Bernhard Neumann
Journal:  J Neurol       Date:  2021-05-10       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.